The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Tascioglu F, Colak O, Armagan O, Alatas O, Oner C

Rheumatology international2 Feb 2005Cited by 21 (Europe PMC)

PMID15688191DOI10.1007/s00296-004-0496-3PepBankPUB-15688191

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, femoral neck BMD was less favorable with calcitonin than alendronate (P < 0.001).
In plain wordsIn women with RA receiving glucocorticoids, femoral neck bone density was less favorable with calcitonin than alendronate.
Peptide
Calcitonin-salmon
Outcome
DecreaseFemoral neck BMD versus alendronate
Study
n: not reported in source
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Source sentences
Summary
The difference between the groups with respect to the femoral neck and trochanteric BMD was statistically significant ( P < 0.001 and P < 0.05, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
Over 2 years, the lumbar spine (4.34%, P < 0.001), femoral neck (2.52%, P < 0.05), and trochanteric (1.29%, P < 0.05) BMD in the alendronate group increased significantly. The sCT treatment increased lumbar spine BMD (1.75%, P < 0.05), whereas a significant bone loss occurred at the femoral neck at…
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819104
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, trochanteric BMD was less favorable with calcitonin than alendronate (P < 0.05).
In plain wordsIn women with RA receiving glucocorticoids, trochanteric bone density was less favorable with calcitonin than alendronate.
Peptide
Calcitonin-salmon
Outcome
DecreaseTrochanteric BMD versus alendronate
Study
n: not reported in source
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Source sentences
Summary
The difference between the groups with respect to the femoral neck and trochanteric BMD was statistically significant ( P < 0.001 and P < 0.05, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
Over 2 years, the lumbar spine (4.34%, P < 0.001), femoral neck (2.52%, P < 0.05), and trochanteric (1.29%, P < 0.05) BMD in the alendronate group increased significantly.
Summary · context
A nonsignificant decrease in the trochanteric region was observed in the sCT group (-0.81%).
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819105
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, DPD favored alendronate over calcitonin at all time points (P = 0.001).
In plain wordsIn women with RA receiving glucocorticoids, DPD results favored alendronate over calcitonin.
Peptide
Calcitonin-salmon
Outcome
IncreaseDPD versus alendronate
Study
n: not reported in source
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Source sentences
Summary
A significant difference was found in the DPD and BAP levels between the two treatment groups in favor of the alendronate group at all time points ( P = 0.001 and P < 0.05, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819109
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, BAP favored alendronate over calcitonin at all time points (P < 0.05).
In plain wordsIn women with RA receiving glucocorticoids, BAP results favored alendronate over calcitonin.
Peptide
Calcitonin-salmon
Outcome
IncreaseBAP versus alendronate
Study
n: not reported in source
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Source sentences
Summary
A significant difference was found in the DPD and BAP levels between the two treatment groups in favor of the alendronate group at all time points ( P = 0.001 and P < 0.05, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819110
05HumanNon-randomized trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, calcitonin increased lumbar spine BMD by 1.75% (P < 0.05).
In plain wordsIn women with RA receiving glucocorticoids, calcitonin increased lower spine bone density from baseline.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change from baseline
1.75%
salmon calcitonin group
Source sentences
Summary
The sCT treatment increased lumbar spine BMD (1.75%, P < 0.05), whereas a significant bone loss occurred at the femoral neck at month 24 (-3.76%, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819101
06HumanNon-randomized trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, femoral neck BMD fell 3.76% from baseline at month 24 in the calcitonin group (P < 0.01).
In plain wordsIn women with RA receiving glucocorticoids, femoral neck bone density decreased from baseline during calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
DecreaseFemoral neck BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Measurements
Femoral neck BMD change from baseline
−3.76%
salmon calcitonin group
Source sentences
Summary
The sCT treatment increased lumbar spine BMD (1.75%, P < 0.05), whereas a significant bone loss occurred at the femoral neck at month 24 (-3.76%, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819102
07HumanNon-randomized trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, trochanteric BMD decreased nonsignificantly by 0.81% with calcitonin.
In plain wordsIn women with RA receiving glucocorticoids, trochanteric bone density did not change significantly with calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeTrochanteric BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Measurements
Trochanteric BMD change from baseline
−0.81%
salmon calcitonin group
Source sentences
Summary
A nonsignificant decrease in the trochanteric region was observed in the sCT group (-0.81%).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819103
08HumanNon-randomized trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, calcitonin reduced urinary DPD nonsignificantly by 5.77%.
In plain wordsIn women with RA receiving glucocorticoids, urinary DPD did not change significantly with calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeUrinary DPD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Measurements
Urinary DPD change from baseline
−5.77%
salmon calcitonin group
Source sentences
Summary
The decreases in urinary DPD (-21.87%, P < 0.001), serum BAP (-10.60%, P < 0.01), and OC (-19.59%, P < 0.05) values were statistically significant in the alendronate group, whereas nonsignificant decreases were observed in the sCT group (-5.77%, -1.96%, and -4.31%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819106
09HumanNon-randomized trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, calcitonin reduced serum BAP nonsignificantly by 1.96%.
In plain wordsIn women with RA receiving glucocorticoids, serum BAP did not change significantly with calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeSerum BAP
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Measurements
Serum BAP change from baseline
−1.96%
salmon calcitonin group
Source sentences
Summary
The decreases in urinary DPD (-21.87%, P < 0.001), serum BAP (-10.60%, P < 0.01), and OC (-19.59%, P < 0.05) values were statistically significant in the alendronate group, whereas nonsignificant decreases were observed in the sCT group (-5.77%, -1.96%, and -4.31%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819107
10HumanNon-randomized trialEfficacy outcome
In postmenopausal women with RA receiving glucocorticoids, calcitonin reduced serum osteocalcin nonsignificantly by 4.31%.
In plain wordsIn women with RA receiving glucocorticoids, serum osteocalcin did not change significantly with calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeSerum osteocalcin
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU/day · intranasal · 24 monthsAs given in this study (human).
Measurements
Serum osteocalcin change from baseline
−4.31%
salmon calcitonin group
Source sentences
Summary
The decreases in urinary DPD (-21.87%, P < 0.001), serum BAP (-10.60%, P < 0.01), and OC (-19.59%, P < 0.05) values were statistically significant in the alendronate group, whereas nonsignificant decreases were observed in the sCT group (-5.77%, -1.96%, and -4.31%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Summary · context
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months.
Report a problemFND-1568819108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms